Ablynx NV established Ablynx Inc., a subsidiary in the U.S.
Daniel Schneider will head the unit as general manager with the goal of commercializing caplacizumab in North America.
If approved by regulatory authorities, caplacizumab would be the first therapeutic specifically indicated to treat acquired thrombotic thrombocytopenic purpura.